Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Department of Justice
Daiichi Sankyo
Julphar
Boehringer Ingelheim
AstraZeneca
QuintilesIMS
Queensland Health
Baxter

Generated: July 19, 2018

DrugPatentWatch Database Preview

Lacosamide - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for lacosamide and what is the scope of lacosamide freedom to operate?

Lacosamide
is the generic ingredient in one branded drug marketed by Ucb Inc and is included in three NDAs. There is one patent protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lacosamide has twenty-two patent family members in eleven countries.

There are twenty-two drug master file entries for lacosamide. Three suppliers are listed for this compound. There are four tentative approvals for this compound.
Pharmacology for lacosamide
Synonyms for lacosamide
( )-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide
(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide
(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide;Lacosamide
(2R)-2-acetamido-3-methoxy-N-(phenylmethyl)propanamide
(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide
(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
(2R)-2-acetylamino-N-benzyl-3-methoxypropanamide
(2R)-N-benzyl-2-acetamido-3-methoxypropanamide
(R)-2-acetamido-N-benzyl-3-methoxypropanamide
(R)-2-acetamido-N-benzyl-3-methoxypropionamide
(R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide
(R)-2-Acetylamino-N-benzyl-3-methoxypropionamide
(R)-N-benzyl 2-acetamido-3-methoxypropionamide
(R)-N-benzyl 2-acetamido-3-methoxypropionamide,
(R)-N-benzyl-2-acetamido-3-methoxypropanamide
(R)-N-Benzyl-2-acetamido-3-methoxypropionamide
175481-36-4
2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide, (2R)-
481L364
563KS2PQY5
AB0020074
AB01559947-01
AB1011880
AC-22750
AC1L560M
ADD 234037
ADD 243037
ADD-234037
ADD-243037
AJ-08306
AK-80442
AKOS005146274
AM808141
AN-5196
ANW-58547
BB 0260890
BDBM50300204
CAS-175481-36-4
CHEBI:135939
CHEMBL58323
CJ-00115
CS-0529
CTK8B7781
D05OFX
D07299
DB06218
DEA No. 2746
DSSTox_CID_31455
DSSTox_GSID_57666
DSSTox_RID_97341
DTXSID1057666
EBD27785
Erlosamide
Erlosamide [INN]
Erlosamide, Vimpat, Lacosamide
ertosamide
FT-0650739
GTPL7472
harkeroside
Harkoseride
HY-13015
I01-7424
I14-32137
KS-00000XOQ
KS-1227
Lacosamide (JAN/USAN/INN)
Lacosamide (USAN/INN)
Lacosamide [USAN:INN:BAN]
Lacosamide [USAN]
Lacosamide racemate
Lacosamide solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
Lacosamide; Propanamide,2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (R)-
LS-185541
M-1600
MFCD08272557
MolPort-006-170-142
NCGC00253740-01
OR059448
OR231753
PROPANAMIDE 2-(ACETYLAMINO)-3-METHOXY-N-(PHENYLMETHYL)- (2R)-
Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
RL02246
SCHEMBL35330
SPM 927
SPM-927
SPM-929
SR-01000942286
SR-01000942286-1
ST24026403
TC-064381
Tox21_113857
UNII-563KS2PQY5
V0815
Vimpat
Vimpat (TN)
VPPJLAIAVCUEMN-GFCCVEGCSA-N
Z1550648754
ZINC7673
Tentative approvals for LACOSAMIDE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up10MG/MLSOLUTION;ORAL
➤ Sign Up➤ Sign Up200MGTABLET;ORAL
➤ Sign Up➤ Sign Up150MGTABLET;ORAL

US Patents and Regulatory Information for lacosamide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide SOLUTION;ORAL 022255-001 Apr 20, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-003 Oct 28, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-002 Oct 28, 2008 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for lacosamide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254-001 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide SOLUTION;ORAL 022255-001 Apr 20, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for lacosamide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,773,475 Anticonvulsant enantiomeric amino acid derivatives ➤ Sign Up
6,048,899 Anticonvulsant enantiomeric amino acid derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for lacosamide

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00376 Netherlands ➤ Sign Up PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829
C001/2009 Ireland ➤ Sign Up SPC001/2009: 20091013, EXPIRES: 20220316
C0006 France ➤ Sign Up PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
C/GB09/007 United Kingdom ➤ Sign Up PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Express Scripts
Federal Trade Commission
Chubb
Argus Health
Farmers Insurance
Healthtrust
US Army
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.